Share

Allergan has been granted a patent for HIF-1a prolyl hydroxylase inhibitors, compositions, and methods for treating conditions like Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia. GlobalData’s report on Allergan gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Allergan Ltd - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Allergan, was a key innovation area identified from patents. Allergan's grant share as of February 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

Hif-1a prolyl hydroxylase inhibitors for treating cardiovascular diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Allergan Ltd

A recently granted patent (Publication Number: US11883386B2) discloses a process for preparing a compound with a specific chemical formula. The process involves reacting certain compounds in a series of steps, including the use of a specific catalyst and base in the reaction process. The patent claims also specify the coupling reagents used in the process, highlighting the precise conditions required for the successful preparation of the compound.

Furthermore, the patent outlines the use of [(4'-chloro-3-methoxy-biphenyl-4-carbonyl)-amino]-acetic acid ethyl ester as a key component in the process, along with the catalyst [1,1'-bis (diphenylphosphino)ferrocine]dichloro palladium(II) and the base K3PO4. The specific coupling reagents, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCl) and 1-hydroxybenzotriazole (HOBt), are also highlighted in the patent claims. Overall, the patent provides a detailed and specific process for preparing the compound, emphasizing the importance of each component and step in the reaction sequence.

To know more about GlobalData’s detailed insights on Allergan, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies